High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells

• Published in: Cancer research (Chicago, Ill.) Vol. 64; no. 17; pp. 6337 - 6343
• Main Authors: SERAFINI, Paolo, CARBLEY, Rebecca, NOONAN, Kimberly A, TAN, Gladys, BRONTE, Vincenzo, BORRELLO, Ivan
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.09.2004
• Subjects: Animals; Antineoplastic agents; Biological and medical sciences; Cancer Vaccines - adverse effects; Cancer Vaccines - immunology; CD4-Positive T-Lymphocytes - immunology; Cell Line, Tumor; Dose-Response Relationship, Immunologic; Female; Granulocyte-Macrophage Colony-Stimulating Factor - adverse effects; Granulocyte-Macrophage Colony-Stimulating Factor - immunology; Male; Medical sciences; Mice; Mice, Inbred BALB C; Mice, Transgenic; Myeloid Cells - immunology; Neoplasms, Experimental - immunology; Neoplasms, Experimental - therapy; Pharmacology. Drug treatments; Tumors; Immune response; Suppressor; Vaccine; Myeloid cell; High dose; Granulocyte macrophage colony stimulating factor; Recruitment

Tumor vaccines have shown promise in early clinical trials. Among them, tumor cells genetically engineered to secrete biologically active granulocyte-macrophage colony-stimulating factor (GM-CSF) can generate a systemic antitumor immune response. Although the minimal required GM-CSF dose produced by...